2 result(s) for
|PI Name||Protocol #||Title|
|Bill Chang||STUDY00020018||A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy.|
|Eneida Nemecek||STUDY00020074||A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA)|
You may also qualify for Phase 1 Program trials.
For more information: